Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

被引：0

作者：

Fox, Christopher P. ^{[1
]}

Townsend, William ^{[2
]}

Gribben, John G. ^{[3
]}

Menne, Tobias ^{[4
]}

Kalakonda, Nagesh ^{[5
]}

Williams, Paula ^{[6
]}

Toron, Farah ^{[6
]}

Tyas, Emma ^{[7
]}

Cooper, Miranda ^{[7
]}

Rickards, Joshua ^{[7
]}

Radford, John ^{[8
,9
]}

机构：

[1] Univ Nottingham, Sch Med, Nottingham, England

[2] Univ Coll London Hosp, NHS Fdn Trust, London, England

[3] Barts Hlth NHS Trust, Barts Canc Inst, London, England

[4] Newcastle Tyne Hosp, NHS Fdn Trust, Newcastle Upon Tyne, England

[5] Univ Liverpool, Mol & Clin Canc Med, Liverpool, England

[6] Bristol Myers Squibb, Uxbridge, England

[7] Lumanity, Farnham, England

[8] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, England

[9] Univ Manchester, Manchester, England

来源：

EJHAEM | 2024年 / 5卷 / 05期

关键词：

ASCT; LBCL; outcomes; real-world evidence; TRANSPLANTATION;

D O I：

10.1002/jha2.970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

引用

页码：992 / 997

页数：6

共 50 条

[41] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Harris, Leonard Jeff
Patel, Kruti
Martin, Michael
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
[42] Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era
Fuji, Shigeo
Kida, Shuhei
Nakata, Kayo
Morishima, Toshitaka
Miyashiro, Isao
Ishikawa, Jun
[J]. ANNALS OF HEMATOLOGY, 2021, 100 (09) : 2253 - 2260
[43] Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study
Daneels, Willem
Rosskamp, Michael
Macq, Gilles
Saadoon, Estabraq Ismael
De Geyndt, Anke
Offner, Fritz
Poirel, Helene A.
[J]. FRONTIERS IN ONCOLOGY, 2022, 12
[44] Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)
Rattanathammethee, Thanawat
Norasetthada, Lalita
Bunworasate, Udomsak
Wudhikarn, Kitsada
Julamanee, Jakrawadee
Noiperm, Panarat
Lanamtieng, Theerin
Phiphitaporn, Pisa
Navinpipat, Manassamon
Kanya, Piyapong
Jit-ueakul, Dusit
Wongkhantee, Somchai
Suwannathen, Thanongsak
Chaloemwong, Juthatip
Wong, Peerapon
Makruasi, Nisa
Khuhapinant, Archrob
Prayongratana, Kannadit
Niparuck, Pimjai
Kanitsap, Nonglak
Suwanban, Tawatchai
Intragumtornchai, Tanin
[J]. ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1887 - 1895
[45] Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective
Yang, Hongbo
Hao, Yanni
Chai, Xinglei
Qi, Cynthia Z.
Wu, Eric Q.
[J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (09) : 1016 - 1024
[46] FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
Sharma, Poornima
Kasamon, Yvette L.
Lin, Xue
Xu, Zhenzhen
Theoret, Marc R.
Purohit-Sheth, Tejashri
[J]. CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4331 - 4337
[47] A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Bachy, Emmanuel
Le Gouill, Steven
Di Blasi, Roberta
Sesques, Pierre
Manson, Guillaume
Cartron, Guillaume
Beauvais, David
Roulin, Louise
Gros, Francois Xavier
Rubio, Marie Therese
Bories, Pierre
Bay, Jacques Olivier
Llorente, Cristina Castilla
Choquet, Sylvain
Casasnovas, Rene-Olivier
Mohty, Mohamad
Guidez, Stephanie
Joris, Magalie
Loschi, Michael
Carras, Sylvain
Abraham, Julie
Chauchet, Adrien
La Rochelle, Laurianne Drieu
Deau-Fischer, Benedicte
Hermine, Olivier
Gastinne, Thomas
Tudesq, Jean Jacques
Gat, Elodie
Broussais, Florence
Thieblemont, Catherine
Houot, Roch
Morschhauser, Franck
[J]. NATURE MEDICINE, 2022, 28 (10) : 2145 - 2154
[48] RE-MIND: Comparing Tafasitamab plus Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Zinzani, Pier Luigi
Rodgers, Thomas
Marino, Dario
Frezzato, Maurizio
Barbui, Anna Maria
Castellino, Claudia
Meli, Erika
Fowler, Nathan H.
Salles, Gilles
Feinberg, Bruce
Kurukulasuriya, Nuwan C.
Tillmanns, Sascha
Parche, Stephan
Dey, Debarshi
Fingerle-Rowson, Gunter
Ambarkhane, Sumeet
Winderlich, Mark
Nowakowski, Grzegorz S.
[J]. CLINICAL CANCER RESEARCH, 2021, 27 (22) : 6124 - 6134
[49] FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Bouchkouj, Najat
Kasamon, Yvette L.
de Claro, R. Angelo
George, Bindu
Lin, Xue
Lee, Shiowjen
Blumenthal, Gideon M.
Bryan, Wilson
McKee, Amy E.
Pazdur, Richard
[J]. CLINICAL CANCER RESEARCH, 2019, 25 (06) : 1702 - 1708
[50] Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
Harrysson, Sara
Eloranta, Sandra
Ekberg, Sara
Enblad, Gunilla
Andersson, Per-Ola
Sonnevi, Kristina
Ljungqvist, Maria
Sander, Birgitta
Jerkeman, Mats
Smedby, Karin E.
[J]. LEUKEMIA & LYMPHOMA, 2024, 65 (04) : 534 - 537

← 1 2 3 4 5 →